저분자 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "저분자" in Korean language version.

refsWebsite

Global rank Korean rank

2^nd place

3^rd place

4^th place

3^rd place

9^th place

105^th place

291^st place

amazon.com

Samanen J (2013). 〈Chapter 5.2 How do SMDs differ from biomolecular drugs?〉. Ganellin CR, Jefferis R, Roberts SM. 《Introduction to Biological and Small Molecule Drug Research and Development: theory and case studies》 Kile판. New York: Academic Press. ASIN B00CXO99RG. doi:10.1016/B978-0-12-397176-0.00005-4. ISBN 978-0-12-397176-0. Table 5.13: Route of Administration: Small Molecules: oral administration usually possible; Biomolecules: Usually administered parenterally CS1 관리 - 여러 이름 (링크)

Macielag MJ (2012). 〈Chemical properties of antibacterials and their uniqueness〉. Dougherty TJ, Pucci MJ. 《Antibiotic Discovery and Development》. 801–2쪽. ISBN 978-1-4614-1400-1. The majority of [oral] drugs from the general reference set have molecular weights below 550. In contrast the molecular weight distribution of oral antibacterial agents is bimodal ... between 340 and 450 Da but with another group in the 700–900 molecular weight range.
Samanen J (2013). 〈Chapter 5.2 How do SMDs differ from biomolecular drugs?〉. Ganellin CR, Jefferis R, Roberts SM. 《Introduction to Biological and Small Molecule Drug Research and Development: theory and case studies》 Kile판. New York: Academic Press. ASIN B00CXO99RG. doi:10.1016/B978-0-12-397176-0.00005-4. ISBN 978-0-12-397176-0. Table 5.13: Route of Administration: Small Molecules: oral administration usually possible; Biomolecules: Usually administered parenterally CS1 관리 - 여러 이름 (링크)

Arkin MR, Wells JA (2004년 4월). “Small-molecule inhibitors of protein-protein interactions: progressing towards the dream”. 《Nature Review Drug Discovery》 3 (4): 301–17. doi:10.1038/nrd1343. PMID 15060526.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002년 6월). “Molecular properties that influence the oral bioavailability of drug candidates”. 《J. Med. Chem.》 45 (12): 2615–23. doi:10.1021/jm020017n. PMID 12036371. CS1 관리 - 여러 이름 (링크)
Lipinski CA (2004년 12월). “Lead-and drug-like compounds: the rule-of-five revolution”. 《Drug Discovery Today: Technologies》 1 (4): 337–341. doi:10.1016/j.ddtec.2004.11.007.
Leeson PD, Springthorpe B (2007년 11월). “The influence of drug-like concepts on decision-making in medicinal chemistry”. 《Nat Rev Drug Discov》 6 (11): 881–90. doi:10.1038/nrd2445. PMID 17971784.
Samanen J (2013). 〈Chapter 5.2 How do SMDs differ from biomolecular drugs?〉. Ganellin CR, Jefferis R, Roberts SM. 《Introduction to Biological and Small Molecule Drug Research and Development: theory and case studies》 Kile판. New York: Academic Press. ASIN B00CXO99RG. doi:10.1016/B978-0-12-397176-0.00005-4. ISBN 978-0-12-397176-0. Table 5.13: Route of Administration: Small Molecules: oral administration usually possible; Biomolecules: Usually administered parenterally CS1 관리 - 여러 이름 (링크)

Arkin MR, Wells JA (2004년 4월). “Small-molecule inhibitors of protein-protein interactions: progressing towards the dream”. 《Nature Review Drug Discovery》 3 (4): 301–17. doi:10.1038/nrd1343. PMID 15060526.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002년 6월). “Molecular properties that influence the oral bioavailability of drug candidates”. 《J. Med. Chem.》 45 (12): 2615–23. doi:10.1021/jm020017n. PMID 12036371. CS1 관리 - 여러 이름 (링크)
Leeson PD, Springthorpe B (2007년 11월). “The influence of drug-like concepts on decision-making in medicinal chemistry”. 《Nat Rev Drug Discov》 6 (11): 881–90. doi:10.1038/nrd2445. PMID 17971784.